Key takeaways

  • Axsome Therapeutics reported a Q3 2026 loss of $0.25 per share, significantly better than the estimated $0.63 per share loss.
  • The biopharmaceutical company's revenue reached $259.7 million, surpassing analyst estimates and growing 52% year-over-year.
  • Key products AUVELITY, SUNOSI, and SYMBRAVO fueled substantial sales growth, contributing to an annualized revenue run rate exceeding $1 billion.

Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company, develops and sells medicines for brain and nervous system conditions. Its innovative products include AUVELITY for depression, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine. In the third quarter of 2026, Axsome reported a loss of $0.25 per share, which was smaller than the $0.63-per-share loss analysts estimated.

Q3 revenue reached $259.7 million, significantly above the $249.2 million estimate. This represents a substantial increase of 52% from a year earlier and 19% from the prior quarter. Revenue measures sales before expenses, while earnings per share reflects profit or loss divided by the number of shares.

AUVELITY drove most of this impressive growth. Its sales rose 53% from a year earlier to $207.6 million. SUNOSI sales increased 47% to $48.2 million, while SYMBRAVO sales grew 88% to $3.9 million. The company’s quarterly revenue now exceeds a $1 billion annualized run rate, indicating strong market penetration and future potential.

Axsome’s net loss significantly narrowed to $12.9 million from $47.2 million a year earlier. The loss per share improved substantially from $0.94 to $0.25. As highlighted by Zacks Investment Research, Axsome has consistently beaten revenue estimates in three of the past four quarters, and this marks its first earnings-per-share beat in that period, signaling a positive trend for the pharmaceutical stock.